Navigation Links
NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation

Sanarus' Visica 2(TM) Treatment System Selected as Exclusive Cryoablation

Treatment Technology

PLEASANTON, Calif., Oct. 28 /PRNewswire/ -- The American College of Surgeons Oncology Group (ACOSOG) which just initiated a National Cancer Institute (NCI) funded clinical trial entitled, "A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma," has selected the Visica 2(TM) Treatment System from Sanarus Medical as the exclusive technology to be utilized in the cryoablation portion of this study.

The ACOSOG study protocol (designated as Z1072) will evaluate not only cryoablation but also the ability of Magnetic Resonance Imaging (MRI) to evaluate post-cryoablation efficacy in approximately 100 patients and 20 clinical sites. Patient enrollment into the study is currently anticipated for early 2009. The Phase II Trial is similar to a pilot study conducted by Gary Levine, MD, Medical Director at Hoag Breast Care Center in Newport Beach, Calif., and Steven Poplack, MD, Co-Director of Breast Imaging at Dartmouth Hitchcock Medical Center. Results of the pilot study will be presented for the first time at this year's Radiological Society of North America (RSNA) 94th Scientific Assembly and Annual Meeting in Chicago. Both the pilot study and pending ACOSOG clinical trial share the common clinical protocol elements of cryoablation followed by MRI, surgical resection of the tumor and subsequent pathological evaluation.

"Cryoablation has been used effectively for years to treat a number of medical conditions, including benign breast tumors, so it is a natural progression to study its use in the treatment of breast cancer," said Dr Levine. "We are very encouraged about the promising initial results in our pilot study and believe further research is warranted in order to develop and refine this potential breakthrough breast cancer treatment."

Cryoablation is a minimally invasive non-surgical procedure that uses extreme cold to destroy tumors. The Sanarus Visica System has predominately been used in the cryoablation of non-cancerous tumors called fibroadenomas since its initial FDA market clearance in March of 2002. This office-based procedure, which usually takes less than 20 minutes, involves placing a small needle into the center of the tumor using ultrasound guidance and subsequently freezing and killing the tumor. The safety and efficacy of cryoablation have been well established in over 2,000 fibroadenomas that have been treated with the System to date.

"We are very pleased that ACOSOG chose cryoablation as the preferred thermal ablation modality over other ablation modalities such as radio- frequency (RF), interstitial laser, microwave, or focused ultrasound," said John F. Howe, President and Chief Executive Officer of Sanarus. "We are equally pleased that the award winning Sanarus Visica 2 Treatment System was selected as the preferred cryoablation system. This speaks volumes to the future potential of our System in expanded applications."

The Visica 2 System recently received national recognition with a Wall Street Journal Technology Innovation Award; and the Humanitarian Application of the Year Award from National Instruments.

The ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-center clinical trials and is the only cooperative group whose primary focus is the surgical management of patients with malignant solid tumors. Additional information regarding the ACOSOG clinical trial is available to ACOSOG members via the organizations website under the heading of the Z1072 Clinical Protocol.

About Sanarus Medical

Sanarus Medical is based in Pleasanton, Calif., and is focused on providing patients and physicians with minimally invasive, office-based breast care management solutions from diagnosis to treatment. Using cryoablation technology, Sanarus has developed proprietary technologies to provide breast surgeons and radiologists with a comprehensive and minimally invasive way to diagnose and treat breast patients. The Sanarus technologies change the way that patients are managed, from an operating room-based, surgically intensive care pathway to a more comfortable, cost effective, office-based care pathway. The company's Website is

SOURCE Sanarus Medical
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
2. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
5. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
6. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
7. Qualia Clinical Services Chooses ALPHADAS(R) for Phase I Clinical Trials
8. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
9. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
10. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
11. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
Breaking Medicine Technology:
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
Breaking Medicine News(10 mins):